In 2022, the market size of ANCA Associated Vasculitis was highest in the US among the 7MM, accounting for approximately USD 620 million, which is expected to increase by 2032.

Emerging ANCA Vasculitis therapies in the different phases of clinical trials are- MT-2990, KYV-101, Povetacicept, NM8074, Sparsentan, Abatacept, BDB-001 injection, Avacopan, Iptacopan, ALE.F02 ...

Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group; Avacopan for the Treatment of ANCA-Associated Vasculitis; N Engl J Med. 2021 Feb 18;384 (7):599-609. doi: 10.1056/NEJMoa2023386.

“ANCA-associated vasculitis is officially designated an intractable disease in Japan, indicating a rare disease without any effective treatment but for which long-term treatment is required. There is ...

New-onset ANCA-positive small-vessel vasculitis is a rare but possible complication of COVID-19 vaccination, according to a recent systematic review. Investigators reviewed 34 case reports and ...

Bacterial DNA Motifs Trigger ANCA Production in ANCA-Associated Vasculitis in Remission Tadema H, Abdulahad WH, Lepse N, Stegeman CA, Kallenberg CG, Heeringa P Rheumatology (Oxford). 2011;50:689-696 ...

Send comments and news tips to [email protected]. Cite this: Managing ANCA Vasculitis: Updated British Guideline ‘Transcends’ Specialties - Medscape - May 13, 2025.

Nearly all children with ANCA-associated vasculitis demonstrate active kidney disease at diagnosis, and their renal function status is strongly predictive of outcomes 1 year later, according to ...